Evidence map›Paper›PMID 37573184›Full record

ReviewTrends in microbiology2023

ISG15: its roles in SARS-CoV-2 and other viral infections.

Lucky Sarkar, GuanQun Liu, Michaela U Gack

Open access · greenAbstract readReview
In one paragraph

Review in Trends in microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
6.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. From bats to humans: uncoveringbioRxiv : the preprint server for biology · 2026
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. The Interplay between the Gut and Ketogenic Diets in Health and Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  19. Article
  20. ISG-15, beyond its functions in the cell: a mini review.Cellular and molecular life sciences : CMLS · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Lucky SarkarCleveland Clinic Florida Research and Innovation Center, Port St. Lucie, FL, USA.
GuanQun LiuCleveland Clinic Florida Research and Innovation Center, Port St. Lucie, FL, USA.
Michaela U GackCleveland Clinic Florida Research and Innovation Center, Port St. Lucie, FL, USA. Electronic address: gackm@ccf.org.
Cleveland Clinic Florida · US

Funding

Defining the viral PTMome: Towards the development of novel antiviral approachesDP1AI169444 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI GACK, MICHAELA ULRIKE · 2021 to 2025
$5.6M
Regulation of Host Innate Immunity Against Viral InfectionR01AI087846 · NIAID · UNIVERSITY OF CHICAGO · PI GACK, MICHAELA ULRIKE · 2010 to 2020
$3.9M
Regulation of Host Innate Immunity Against Viral InfectionR37AI087846 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI Michaela Ulrike Gack · 2021 to 2026
$2.8M
Novel Role for Host Immunostimulatory RNA in Antiviral Immune DefenseR01AI165502 · NIAID · CLEVELAND CLINIC LERNER COM-CWRU · PI GACK, MICHAELA ULRIKE · 2021 to 2025
$2.3M
The Role of TRIM23 in Autophagy Mediated Antiviral DefensesR01AI148534 · NIAID · UNIVERSITY OF CHICAGO · PI GACK, MICHAELA ULRIKE · 2020 to 2024
$2.3M
NIAID NIH HHS DP1 AI169444NIAID NIH HHS R01 AI087846NIAID NIH HHS R01 AI148534NIAID NIH HHS R01 AI165502NIAID NIH HHS R37 AI087846
6 · The paper itself

Abstract

Interferon (IFN)-stimulated gene 15 (ISG15), a ubiquitin-like pleiotropic protein and one of the most abundant ISGs, has been studied extensively; however, its roles in SARS-CoV-2 and other viral infections have just begun to be elucidated. Emerging evidence suggests that ISG15 - either in its conjugated or unconjugated 'free' form - acts both intracellularly and extracellularly, and exerts anti- or pro-viral effects. To counteract ISG15's antiviral roles, viruses have evolved sophisticated tactics. Here, we discuss recent advances in ISG15's physiological functions as a post-translational modifier or 'cytokine-like' molecule during SARS-CoV-2 and other viral infections. Furthermore, we highlight the detailed mechanisms viruses use to block ISG15-dependent antiviral defenses. A comprehensive understanding of ISG15 biology in the context of virus infection may spur new therapeutic approaches for a range of viral infectious diseases.

Indexed as

COVID-19Virus DiseasesAntiviral AgentsCytokinesHumansSARS-CoV-2UbiquitinsAntiviral AgentsCytokinesISG15 protein, humanUbiquitinshyperinflammationinnate immunityISG15ISGylationSARS-CoV-2viral evasion

Identifiers

PMID37573184
PMCPMC10840963
OpenAlexW4385719242

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.